Publications

5808 Results

Molecular signatures implicate innate immune cells, fibrosis, and angiogenesis in survival following R-CHOP treatment of diffuse large B cell lymphoma

Authors
G Lenz;G Wright;SS Dave;W Xiao;H Zhao;W Xu;B Tan;N Goldschmidt;J Iqbal;J Vose;M Bast;K Fu;DD Weisenburger;TC Greiner;JO Armitage;A Kyle;L May;RD Gascoyne;JM Connors;G Troen;H Holte;H Holte;S Kvaloy;D Dierickx;G Verhoef;J Delabie;EB Smeland;P Jares;A Martinez;A Lopez-Guillermo;E Montserrat;E Campo;RM Braziel;TP Miller;LM Rimsza;JR Cook;B Pohlman;JW Sweetenham;RR Tubbs;RI Fisher;E Hartmann;A Rosenwald;G Ott;HK Muller-Hermelink;D Wrench;TA Lister;ES Jaffe;WH Wilson;LM Staudt
Journal / Conference
Blood 112(11)181 abst. 475
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Genome-wide expression profiling predicts treatment outcome in classical hodgkin lymphoma

Authors
C Steidl;T Lee;SP Shah;G Han;T Nayar;A Delaney;WC Chan;A Rosenwald;LM Rimsza;E Campo;ES Jaffe;LM Staudt;G Lenz;JM Connors;RD Gascoyne
Journal / Conference
Blood 112(11):196 Abst. 520
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Genetic abnormalities involved in the development and progression of follicular lymphoma

Authors
KE Deffenbacher;GL Wright;J Iqbal;H Geng;D O'Shea;TA Lister;JF Fitzgibbon;K Fu;A Liu;D Weisenburger;TC Greiner;RD Gascoyne;A Rosenwald;E Campo;LM Rimsza;J Delabie;ES Jaffe;LM Staudt;WC Chan
Journal / Conference
Blood 112(11):714, Abst. 2049
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclosphosphamide in women with operable, node positive breast cancer

Authors
PA Ganz;SR Land;CE Geyer;JP Costantino;ER Pajon;L Fehrenbacher;JN Atkins;JA Pollikoff;VE Vogel;JK Erban;RB Livingston;EA Perez;EP Mamounas;N Wolmark;SM Swain
Journal / Conference
San Antonio Breast Cancer Symposium, Abstract #76
Year
2008
Research Committee(s)
Breast

Phase II evaluation of neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube, or primary peritoneal cancer: A Southwest Oncology Group study

Authors
A Tiersten;P Liu;H Smith;SP Wilczynski;WR Robinson;M Markman;DS Alberts
Journal / Conference
Gynecologic Oncology 108(3) suppl. 1:S3
Year
2008
Research Committee(s)
Gynecologic
Study Number(s)
S0009

Interim futility analysis with intermediate endpoints

Authors
B Goldman;M LeBlanc;J Crowley
Journal / Conference
Clinical Trials 5(1):14-22
Year
2008
Research Committee(s)
Breast, Gastrointestinal, Genitourinary, Head and Neck, and Lung
PMID
PMID18283075
Study Number(s)
S0205, S0427, SWOG-9509, S9921, S9927

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials [PMC2645100; PMID19001332]

Authors
C Vale;JF Tierney;LA Stewart;M Brady;K Dinshaw;A Jakobsen;MK Parmar;G Thomas;T Trimble;DS Alberts;H Chen;S Cikaric;PJ Eifel;M Garipagoaglu;H Keys;N Kantardzic;P Lal;R Lanciano;F Leborgne;V Lorvidhaya;H Onishi;RG Pearcey;E Pras;K Roberts;PG Rose;CW Whitney
Journal / Conference
Journal of Clinical Oncology 26(25):5802-5812
Year
2008
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12)

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma [PMID 18094721]

Authors
A Palumbo;SV Rajkumar;MA Dimopoulos;PG Richardson;J San Miguel;B Barlogie;J Harousseau;JA Zonder;M Cavo;M Zangari;M Attal;A Belch;S Knop;D Joshua;O Sezer;H Ludwig;D Vesole;J Blade;R Kyle;J Westin;D Weber;S Bringhen;R Niesvizky;A Waage;M von Lilienfeld-Toal;S Lonial;SJ Morgan;RZ Orlowski;K Shimizu;KC Anderson;M Boccadoro;BG Durie;P Sonneveld;MA Hussein
Journal / Conference
Leukemia 22(2):414-423
Year
2008
Research Committee(s)
Myeloma
Study Number(s)
S0204, S0232

The Southwest Oncology Group: progress in cancer research [PMID18929152]

Authors
CA Coltman
Journal / Conference
Seminars in Oncology 35(5):545-552
Year
2008
Research Committee(s)
Breast, Cancer Control, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Myeloma, Prevention, Screening, and Surveillance, and Sarcoma
Study Number(s)
S0000, S0003, S0033, SWOG-7436, SWOG-7808, SWOG-7827, SWOG-8006, SWOG-8216/38, SWOG-8378, SWOG-8412, SWOG-8494 (INT-0036), SWOG-8501 (INT-0051), SWOG-8507, SWOG-8516 (INT-0067), SWOG-8591(NCI Intergroup #0035), SWOG-8593 (INT-0065), SWOG-8600, SWOG-8642, SWOG-8691 (INT-0073), SWOG-8692 (INT-0075), SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891), SWOG-8736 (INT-0093), SWOG-8794, SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12), SWOG-8809, SWOG-8812, SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817), SWOG-8894 (INT-0105) (EST-2889), SWOG-8897, SWOG-8949, SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195), SWOG-9126, SWOG-9133, SWOG-9210, SWOG-9217, SWOG-9308, SWOG-9509, S9916

Prostate cancer chemorevention update of the prostate cancer prevention trial findings and implications for clinical practice

Authors
JA Sarvis;IM Thompson
Journal / Conference
Current Oncology Reports 10(6):529-532
Year
2008
Research Committee(s)
Cancer Control
PMID
PMID: 18928669
Study Number(s)
SWOG-9217